Latest studies
- RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaFinland - RecruitingTherapeutic confirmatory (Phase III)
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
This clinical trial compares a new targeted drug called JDQ443 with standard chemotherapy (docetaxel). It is for adults with advanced non-small cell lung cancer that carries a specific genetic change called KRAS G12C. Researchers want to find out which treatment keeps cancer from growing for longer.
Advanced non-small cell lung cancer harboring the KRAS G12C mutationFinland - CompletedPhase II/III
ENRICH Ibrutinib for untreated mantle cell lymphoma
The ENRICH study is testing a targeted medicine called ibrutinib for people aged 60 and older who have newly diagnosed mantle cell lymphoma. Researchers want to see if ibrutinib, taken with an antibody drug, works better and causes fewer side effects than traditional chemotherapy.
Mantle cell lymphoma (MCL)Finland - Authorised (with conditions)Human Pharmacology (Phase I)- Bioequivalence Study
Systemic Bioavailability and Bioequivalence of Topical Diclofenac Fysioline 23.2 mg/g gel compared with Diclofenac Diethylamine - Voltaren Forte 2.32% gel
This study compares a new pain-relief gel (Diclofenac Fysioline) with an established brand (Voltaren Forte). Both gels treat muscle and joint aches. Researchers want to see if the new gel enters the bloodstream in the same way and works just as effectively as the trusted brand.
Bioequivalence, musculoskeletal pain painFinland - AuthorisedTherapeutic confirmatory (Phase III)
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
This phase 3 study tests an investigational medicine called salanersen (BIIB115) for people aged 15 to 60 with spinal muscular atrophy (SMA). Researchers want to see if it helps improve physical movement, arm strength, and walking ability over time in people new to treatment or previously treated with risdiplam.
Spinal Muscular AtrophyFinland - AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis and Healthy Volunteers (FOL-CARD)
This study tests a new imaging dye for PET scans called Al[18F]F-NOTA-folate. Researchers want to see if it can clearly detect heart inflammation in cardiac sarcoidosis or heart valve infections in infective endocarditis. It is open to affected adults and healthy volunteers aged 18 and over.
Cardiac Sarcoidosis, Infective endocarditisFinland - AuthorisedPhase I and Phase II (Integrated)- Other
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
This clinical trial is testing a new tablet called S241656 for adults with certain blood and bone marrow cancers, including acute myeloid leukaemia. Doctors want to find out what dose is safe, how the body handles the medicine, and whether it can help control or shrink the cancer.
Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome /Acute Myeloid Leukemia (MDS/AML) or Chronic Myelomonocytic Leukemia (CMML)Finland - AuthorisedTherapeutic exploratory (Phase II)
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
This study looks at a new drug combination for older or frail adults with diffuse large B-cell lymphoma, a type of blood cancer. Researchers want to see if adding an antibody drug called epcoritamab to standard, gentler chemotherapy helps clear the cancer better and keeps people well for longer.
Diffuse large B-cell lymphoma (DLBCL)Finland - AuthorisedTherapeutic use (Phase IV)
Effects of General Anaesthetic Agents on the Efficacy of Electroconvulsive Therapy and EEG Changes in Patients with Depression
This study looks at people having electroconvulsive therapy (ECT) for severe depression. Researchers want to find out which common anaesthetic medicines help ECT work best and quickest. By checking brain activity and mood scores, the study aims to make future ECT treatments safer and more effective.
Severe unipolar depression treated with electroconvulsive therapyFinland - AuthorisedTherapeutic use (Phase IV)
Antibiotic Prophylaxis in Hematopoietic Stem Cell Transplantation: a Randomised Controlled Trial - The ANTURA trial
This study tests whether taking an antibiotic called levofloxacin helps prevent serious blood infections in adults having a donor stem cell transplant. Patients are given either the antibiotic or a dummy treatment (placebo) to see if preventive medicine safely lowers infection rates and improves recovery after transplantation.
Primary immunodeficiencies and other non‑malignant disorders treated with allogeneic hematopoietic stem cell transplantation.(acute leukemias, myelodysplastic syndromes, lymphomas, and other malignant disorders for which allogeneic HSCT is indicated)Finland - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, randomized, placebo-controlled, observer-blind study in adults 60 years and older to evaluate the efficacy, safety, and immunogenicity of a bivalent protein vaccine candidate against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
This clinical trial is testing a new combination vaccine designed to protect older adults against two common chest viruses: RSV and HMPV. Researchers want to find out how well the vaccine prevents lung infections, how safe it is, and whether it helps the immune system build strong protective defences.
Infections and infestationsFinland - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisFinland - RecruitingPHASE2
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
This study tests a new drug called bexmarilimab alongside a standard treatment (azacitidine) for adults newly diagnosed with higher-risk myelodysplastic syndromes (MDS). Researchers want to find the safest and most effective dose, and see if combining these treatments helps manage this blood condition better than standard treatment alone.
Higher Risk Myelodysplastic SyndromesFinland - RecruitingHuman Pharmacology (Phase I)- Other
A study to see how a single increasing dose of the oral drug AD-700 affects the ability of a CT scan to detect activated brown fat in healthy people
This early-stage study is testing an experimental medicine called AD-700 in healthy men aged 18 and over. Researchers want to see if a single dose can activate brown fat—a type of fat that burns energy—and whether this activity can be clearly seen on a CT scan.
Metabolism dysfunctionFinland - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
This study tests whether a weekly drip of a protein medicine can protect the lungs in adults with alpha-1 antitrypsin deficiency. Researchers want to see if two different doses can slow down lung damage and reduce severe chest flare-ups compared to a dummy treatment.
Pulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyFinland - RecruitingTherapeutic confirmatory (Phase III)
Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva
This Phase 3 clinical trial is testing a new medicine called garetosmab for adults with fibrodysplasia ossificans progressiva (FOP). Researchers want to see if garetosmab can safely stop or slow down abnormal bone growth in muscles and joints, reduce painful flare-ups, and help protect movement and daily function.
Fibrodysplasia Ossificans ProgressivaFinland - AuthorisedPhase I and Phase II (Integrated)- Other
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
This study is testing an experimental medicine called pumitamig for adults with advanced kidney cancer. Doctors want to see how safe it is on its own or alongside other cancer drugs, and whether it can help shrink tumours or stop the cancer from getting worse.
Advanced Renal Cell CarcinomaFinland - AuthorisedTherapeutic confirmatory (Phase III)
C4931004 - A Phase 3, Randomized Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Catch-Up Vaccination Regimen of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Children and Adolescents
This study looks at a vaccine called Prevenar 20 in healthy children and teenagers aged 15 months to 17 years. Researchers want to see how safe the vaccine is and how well it helps the body build protection against bacteria that cause ear infections, chest infections, and meningitis.
Pneumoccoccal ImmunisationFinland - AuthorisedTherapeutic confirmatory (Phase III)
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy
This study looks at a medicine called venglustat for children aged 2 to 11 with Gaucher disease type 3. Researchers want to find out if venglustat works as well as the standard treatment, Cerezyme, at keeping the spleen, liver, and blood healthy over one year.
Immune system diseasesFinland - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
This study tests a new medicine called APAC for people with kidney failure having fistula surgery. Doctors place the medicine directly into the arm during the operation. The aim is to see if APAC safely helps the blood vessel grow wide and strong enough for haemodialysis treatments.
End stage kindey diseaseFinland - AuthorisedHuman Pharmacology (Phase I)- Other
An open-label, randomized, single-dose, two-way cross-over study to assess the tolerability and pharmacokinetics of NRT001 nicotine buccal film compared with an oromucosal nicotine spray in adult occasional nicotine users
This early-stage study looks at a new nicotine film that dissolves inside your cheek, called NRT001. Researchers want to see how well it is tolerated and how quickly nicotine enters the body compared to a standard nicotine mouth spray in adults who use nicotine occasionally.
Nicotine Replacement TherapyFinland - AuthorisedTherapeutic exploratory (Phase II)
ASPIRE-1; Individual and combined endothelin receptor and SGLT2 antagonism in adults with type 1 diabetes mellitus and chronic kidney disease: a Phase 2, multicenter, open-label randomized cross-over trial
The ASPIRE-1 clinical trial is looking at new ways to protect the kidneys in adults with type 1 diabetes and chronic kidney disease. Researchers want to see if combining two different medicines works better to reduce kidney strain and protein leaks than taking just one medicine on its own.
Chronic Kidney Disease, Type 1 DiabetesFinland - RecruitingTherapeutic confirmatory (Phase III)
Randomized, Observer-Blind, Active-Controlled, Phase III Study in Adults ≥ 60 years of Age to Assess the Safety and Immunogenicity of Abbott’s Candidate High-Dose Influenza Vaccine.
This study tests a new high-dose flu vaccine designed for older adults. As we age, our immune systems need extra help to fight off illness. Researchers want to see if this new jab safely creates strong protection against three flu strains compared to existing flu vaccines.
Influenza immunisationFinland - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study
This early-stage clinical trial is for healthy adult volunteers. Researchers are studying how three substances—ketamine, cannabidiol (CBD), and cobicistat—interact when taken together. The aim is to see how the body absorbs and breaks down these medicines, helping doctors understand if they can be safely combined in the future.
Terveet vapaaehtoiset tutkittavatFinland - AuthorisedTherapeutic confirmatory (Phase III)
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
This study looks at the long-term safety of a medicine called admilparant for people with pulmonary fibrosis. Researchers want to see how well the body handles the treatment over time, tracking any side effects and checking heart health and blood tests to make sure it is safe to use.
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosisFinland - AuthorisedTherapeutic exploratory (Phase II)
An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.
This study is an extension study for adults who have already taken the medicine alpelisib in a previous clinical trial for breast cancer or a rare overgrowth condition called PROS. It allows patients to continue their treatment while doctors monitor its long-term safety and how well it keeps working.
• PROS (PIK3CA‑Related Overgrowth Spectrum) and,• Breast Neoplasms [UMLS CUI term]Finland - AuthorisedTherapeutic confirmatory (Phase III)
Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial
This clinical trial looks at whether a friendly bacteria liquid called Mutaflor can help stop urinary tract infections (UTIs) from returning in babies and young children. Researchers will compare this probiotic liquid with a simple sugar syrup over six months to see if it reduces infections and hospital stays.
Urinary tract infection or PyelonephritisFinland - AuthorisedTherapeutic use (Phase IV)
Thromboprophylaxis with apixaban during neoadjuvant therapy for muscle-invasive bladder cancer (ACB): An international randomized controlled trial evaluating apixaban versus no anticoagulation in patients scheduled to undergo radical cystectomy or chemoradiotherapy for muscle-invasive bladder cancer
This clinical study looks at whether taking a blood-thinning tablet called apixaban can help prevent blood clots in people receiving treatment for bladder cancer before surgery or radiotherapy. Researchers want to see if this medicine safely stops blood clots forming without causing unwanted bleeding.
Venous thromboembolism (in bladder cancer patients)Finland - AuthorisedTherapeutic confirmatory (Phase III)
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
This phase 3 trial looks at whether an immunotherapy drug called durvalumab helps people with limited-stage small cell lung cancer live longer. It tests if giving durvalumab through a drip after standard chemotherapy and radiotherapy helps keep the cancer from returning.
Small-cell lung cancer, limited stageFinland - RecruitingTherapeutic confirmatory (Phase III)
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
This clinical trial is testing a new investigational medicine called NMRA-335140 for adults living with major depression. Doctors want to see how safe the treatment is over a longer period and whether it helps improve low mood, anxiety, ability to feel pleasure, and overall quality of life.
Major Depressive DisorderFinland - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants with Major Depressive Disorder
This study tests a new daily medicine called NMRA-335140 for adults with major depression. Researchers want to see if this tablet can help ease feelings of sadness and improve the ability to enjoy life over six weeks, comparing it against a dummy pill to ensure fair results.
Major Depressive DisorderFinland - RecruitingTherapeutic confirmatory (Phase III)
Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)
This study is testing a new vaccine to protect babies and toddlers from a common winter bug called RSV. Researchers want to see how well it works, how safe it is, and if it helps stop serious lung infections caused by RSV.
Virus diseasesFinland - RecruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease
This study is testing a new medicine, GV1001, for people with mild to moderate Alzheimer's disease. We want to see if it's safe and if it can help improve memory and thinking over 52 weeks. Half the participants will receive the medicine, and half will receive a dummy injection.
Alzheimer's DiseaseFinland - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study looks at a new drug called niraparib to see if it can help women with advanced ovarian cancer stay well longer after their first round of chemotherapy. It compares niraparib to a dummy pill to find out how effective and safe it is.
Homologous recombination deficiency advanced ovarian cancerFinland - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
This study is looking at a new medicine called Calquence for people with chronic lymphocytic leukemia. Researchers want to see how safe the medicine is by tracking any side effects. They will also check if it helps people get better.
Chronic lymphocytic leukemiaFinland - RecruitingTherapeutic use (Phase IV)
Maternal pertussis immunization in Finland, 4 years (MIFI-4Y)
This study, called MIFI-4Y, looks at how well a special vaccine given to mothers during pregnancy protects their children from whooping cough (pertussis) for up to four years. It's a follow-up to see how strong children's protection is over time.
PertussisFinland - RecruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisFinland - RecruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
This study is testing a new medicine, ISIS 678354, for people with very high levels of a type of fat in their blood called triglycerides. It aims to see if the medicine can lower these levels compared to a dummy medicine.
Severe Hypertriglyceridemia.Finland - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS- 986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
This study is looking at new ways to treat bladder cancer that has grown into the muscle. It compares standard chemotherapy with chemotherapy plus new immunotherapy drugs (like Nivolumab) before and after surgery, to see which approach works best and is safest.
Bladder CancerMuscle-Invasive Bladder CancerFinland - RecruitingTherapeutic exploratory (Phase II)
Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina. A phase II randomized, double-blinded, placebo-controlled study.
This study is testing a new treatment called VEGF-D for severe chest pain (refractory angina). It aims to see if this treatment can help people walk further and feel better, compared to a dummy treatment.
Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina.A phase II randomized, double-blinded, placebo-controlled study.Finland - RecruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaFinland - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called Efavaleukin Alfa for people with moderate to severe ulcerative colitis. It's a long-term study to see how safe and effective the medicine is over a year or two, especially regarding side effects.
Ulcerative Colitis (UC)Finland - RecruitingTherapeutic confirmatory (Phase III)
EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer
This study is looking at a new combination of two drugs, alpelisib and olaparib, for women with a specific type of advanced ovarian cancer that has come back or grown after previous treatment. It compares this combination to standard chemotherapy to see if it works better.
Platinum-resistant or refractory, high-grade serous ovarian cancer withno germline BRCA mutationFinland - RecruitingTherapeutic confirmatory (Phase III)
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 (depemokimab) compared with mepolizumab or benralizumab
This study looks at a new medicine called depemokimab for severe asthma with high eosinophils. It compares it to existing treatments like mepolizumab and benralizumab over a year to see if it's just as good at preventing asthma attacks and improving control.
Severe asthma with an eosinophilic phenotypeFinland - RecruitingPhase II and Phase III (Integrated)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study is looking at a new medicine called spesolimab for a skin condition called Hidradenitis Suppurativa, or HS. It's an extension study, meaning some people might have tried it before. Researchers want to see how safe and effective it is over a longer time.
Hidradenitis Suppurativa (HS)Finland - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Finland - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.
Acute Myeloid LeukemiaFinland - RecruitingTherapeutic exploratory (Phase II)
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
This study is for women with advanced ovarian (or related) cancer that has come back and isn't responding to platinum-based chemotherapy. Researchers are comparing a new treatment called Luveltamab Tazevibulin with standard chemotherapy to see if it works better and is safe.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)Finland - RecruitingTherapeutic exploratory (Phase II)
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
This study is looking at a new combination treatment for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It aims to see how well these medicines keep the cancer from growing and how safe they are.
chronic lymphocytic leukemiaFinland - RecruitingPhase III and phase IV (Integrated)
A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.
This study is testing a new vaccine for older adults against a common chest infection called RSV. It looks at how well the vaccine works, if it causes side effects, and how safe it is for people aged 60 and over.
Respiratory Syncytial Virus InfectionsFinland